SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries turns green on the bourses

08 Dec 2011 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs 512.00, up by 1.05 points or 0.21% from its previous closing of Rs 510.95 on the BSE.

The scrip opened at Rs 513.00 and has touched a high and low of Rs 516.85 and Rs 505.50 respectively. So far 25541 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 539.90 on 05-Dec-2011 and a 52 week low of Rs 392.05 on 09-Feb-2011.

Last one week high and low of the scrip stood at Rs 539.90 and Rs 508.30 respectively. The current market cap of the company is Rs 52913.06 crore.

The promoters holding in the company stood at 63.72% while Institutions and Non-Institutions held 25.48% and 10.81% respectively.

Sun Pharmaceutical Industries’ promoter Dilip Shanghvi has bought a minority stake in Natco Pharma for 18.34 crore. Shanghvi, among the richest men in India, bought Rs 7.25 lakh shares, or 2.6% of Natco Pharma, from Orange Mauritius Investments at Rs 253 apiece. Natco’s promoters and the promoter group own 63% of the company.

Natco Pharma, which employs 2,500 people, has five manufacturing facilities spread across India with dedicated modern research laboratories and capabilities in new drug development. It sells cancer medicines.

Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1834.40 -16.00 (-0.86%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×